查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098413

PD-1 和 PD-L1 抑制劑市場－2026 年至 2032 年全球市場預測

PD-1 & PD-L1 Inhibitors Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，PD-1 和 PD-L1 抑制劑市場將成長至 1,149.5 億美元，複合年成長率為 14.96%。

主要市場統計數據
基準年 2025 433億美元
預計年份：2026年 496.1億美元
預測年份 2032 1149.5億美元
複合年成長率 (%) 14.96%

PD-1 和 PD-L1 抑制劑是免疫檢查點抑制劑，旨在透過抑製程序性死亡蛋白 1 (PD-1) 路徑或其配體介導的免疫逃脫訊號，從而恢復抗腫瘤 T 細胞活性。這些療法已成為查核點，並已獲得監管部門批准，納入臨床指南，並在黑色素瘤、非小細胞肺癌、腎細胞癌、尿路上皮癌、頭頸癌、肝細胞癌、乳癌、子宮頸癌、三陰性乳腺癌以及微衛星不穩定性高 (MSI-H) 或錯配修復缺陷 (dMMR) 腫瘤中進行了廣泛的臨床評估。目前，基於生物標記的治療選擇正日益成為指導此類治療的重要因素，這些生物標記包括 PD-L1 表達、腫瘤突變負荷 (TMB)、MSI-H/dMMR 狀態以及新興的免疫微環境特徵。在臨床實踐中，治療方案正從晚期轉移性癌症轉向早期癌症、輔助性治療、輔助性治療和手術全期護理，而維持免疫記憶和提高無事件生存期是這些領域的主要研究挑戰。從醫療保健系統、保險公司、監管機構和生物製藥相關人員的角度來看，PD-1和PD-L1抑制劑的現狀具有以下特點：科學創新、聯合治療的不斷擴展、安全性管理要求，以及在保持循證用藥的同時，提高患者公平獲得治療的必要性。

PD-1和PD-L1抑制劑領域的變革性變化

PD-1 和 PD-L1 抑制劑的現狀正經歷重大變革，其臨床開發正從單藥治療轉向與化療、抗血管生成藥物、分子標靶治療、放射線治療、癌症疫苗、細胞療法和新一代免疫調節劑的合理聯合治療。早期早期療育是關鍵的轉變，查核點抑制劑正在輔助性治療、輔助性治療和手術全期治療方案中進行評估和應用，其中病理緩解、無事件生存期和降低長期復發率是主要終點。精準腫瘤學也在重塑治療路徑，生物標記檢測變得更加標準化和多樣化，從單一標記 PD-L1 免疫組化擴展到複雜的免疫分析、基因組不穩定性標記、循環腫瘤 DNA 和抗藥性特徵。同時，該領域正透過改善監測、多學科照護模式和最大限度減少類固醇使用的管理方法，不斷提升對免疫相關不利事件的應對能力。在監管科學領域，腫瘤類型無關適應症、確證性證據要求、真實世界數據（REW）生成以及早期准入系統的適應性等方面均取得了進展。另一個顯著變化是生物相似藥和國產查核點抑制劑在某些地區的出現，這促使政策制定者更加關注藥物的可負擔性、互換性、採購標準、藥物安全監測以及治療的連續性。

人工智慧對查核點抑制劑研發的累積影響

人工智慧在PD-1和PD-L1抑制劑的價值鏈中扮演著日益重要的角色，尤其是在生物標記發現、患者分層、臨床試驗最佳化、醫學影像分析和真實世界證據解讀方面。機器學習模型正被應用於數位病理學、放射組學、基因組學、轉錄組學和電子健康記錄，以幫助識別免疫反應性腫瘤表現型，並提高預測治療療效和抗藥性的準確性。在臨床開發中，人工智慧可以輔助方案設計、完善合格組標準、進行研究中心可行性分析、病患配對、不利事件預警和自適應試驗監測。在臨床實踐中，人工智慧驅動的決策支援可以幫助臨床醫生將PD-L1狀態、分子實驗室檢測結果、治療史、共病、器官功能和免疫毒性風險整合到實證治療路徑中。然而，負責任地實施人工智慧需要透明的模型檢驗、多樣化的訓練資料集、監管監督、可解釋性、網路安全以及防止演算法偏差的安全措施。人工智慧的累積影響不會取代臨床判斷，而是會加速精準免疫腫瘤學的發展，幫助將複雜的生物學和真實世界數據轉化為更及時、可重複和以患者為中心的治療決策。

關於PD-1和PD-L1抑制劑引入的關鍵區域性見解

亞太地區是PD-1和PD-L1抑制劑應用極為活躍的地區，這主要得益於該地區龐大的癌症患者群體、臨床試驗的快速擴張、生物標記檢測能力的提升以及免疫腫瘤學領域積極的監管參與。中國正在加速國內查核點抑制劑的研發和核准，而日本、韓國、澳洲、印度和東南亞等市場基於指南的推廣應用仍在以不同的速度推進，這取決於保險報銷、診斷基礎設施以及腫瘤領域的人力資源結構。在歐洲，實證醫學的應用正透過集中監管評估、衛生技術評估、國家醫保報銷談判以及不斷擴大的生物標記檢測網路穩步推進，但由於成本效益閾值和醫療預算優先事項的不同，各國的可及性存在差異。北美仍然是PD-1和PD-L1抑制劑應用最成熟的地區之一，這得益於先進的癌症中心、全面的分子診斷、保險公司的嚴格審查、完善的臨床試驗基礎設施以及免疫療法在腫瘤學指南中的廣泛應用。拉丁美洲的特點是臨床技術不斷進步，對免疫腫瘤學的需求日益成長，但公立和私立醫療系統之間的醫療資源分配仍然極不均衡，報銷期限、病理檢測的標準化以及藥品採購政策都會影響藥物的可及性。非洲是一個新興地區，免疫腫瘤學的可及性正在擴大，其發展取決於腫瘤學基礎設施、病理檢測能力、資金籌措機制、低溫運輸物流、癌症登記系統的發展以及旨在改善診斷和治療的區域夥伴關係。在中東，尤其是在高所得海灣國家的醫療系統中，腫瘤學的現代化、對專科癌症中心的投資以及精準醫療計畫正在推進，但全部區域的醫療資源取得仍然取決於報銷機制和專科醫生的數量。

影響免疫腫瘤學領域准入和政策的關鍵群體特定見解。

儘管許多北約成員國擁有先進的腫瘤醫療體系，並具備成熟的臨床試驗網路和指南採納機制，但免疫療法的可及性仍取決於各國的醫療財政狀況、公共衛生優先事項以及各國特定的監管和報銷機制。七國集團（G7）國家通常擁有健全的監管、診斷、臨床研究和報銷體系，支持基於實證醫學的PD-1和PD-L1抑制劑應用，但支付方評估和基於價值的准入政策仍然具有重要影響。金磚國家的發展各不相同。中國正在建立強大的國內研發能力，印度在兼顧可負擔性的同時擴大癌症治療的覆蓋範圍，巴西正在將免疫療法整合到分散的公共和私人醫療體系中，俄羅斯維持著自身的監管和採購體系，而南非在臨床專業知識不斷成長的同時，也面臨著基礎設施和資金籌措的限制。歐盟透過集中核准、藥物安全監測和衛生技術評估流程，為評估查核點抑制劑提供了一個系統的環境，但報銷條件和實際可近性仍然由各個成員國自行決定。在東協地區，PD-1和PD-L1抑制劑的應用正透過國家癌症控制工作、私人腫瘤醫療服務以及參與多國臨床試驗而逐步推進。然而，由於成員國之間在生物標記檢測、醫療覆蓋範圍和專科醫生分佈方面存在差異，患者獲得這些藥物的機會仍然不穩定。在海灣合作理事會（GCC）國家，透過加強對三級癌症治療、國家醫療保險體系和精準醫療舉措的投入，免疫腫瘤治療的可近性正在加強。而在高所得國家，醫療體系往往優先考慮快速推廣指引建議的治療方案。

各國對PD-1和PD-L1抑制劑引入情況的關鍵見解

由於國內研發投入龐大、臨床試驗活動活躍以及健保覆蓋範圍不斷擴大，中國已成為免疫腫瘤學領域的重要中心。同時，美國仍然是PD-1和PD-L1抑制劑在臨床和法規環境，其藥物已廣泛應用於已獲批的腫瘤類型，擁有先進的生物標記檢測技術、活躍的臨床試驗以及強大的真實世界證據積累，但醫保體系的設計和管理方式會影響藥物的可及性。日本在臨床證據、藥物安全監測和醫保報銷方面保持著高標準，已獲批適應症的藥物使用率不斷提高，並且在胃癌、肺癌以及該地區其他常見癌症的治療方面也開展了積極的研究。在印度，查核點抑制劑在三級癌症中心的應用正在不斷擴大，合理的價格、較低的自付費用、生物相似藥的供應以及分子診斷的可及性是其廣泛應用的關鍵因素。德國則受益於其強大的腫瘤學基礎設施、早期上市後准入機制以及系統性的療效評估。同時，在英國，PD-1和PD-L1抑制劑透過嚴格的醫療技術評估、管理式用藥方案、國家指南和分子檢測項目得以整合。澳洲透過公共醫療保險報銷和強大的腫瘤網路支持基於指南的用藥，而法國則將集中評估與國家醫療保險報銷途徑和強大的癌症網路相結合。韓國將先進的癌症治療、生物標記檢測和積極的臨床研究與國家醫療保險報銷評估相結合。在義大利和西班牙，臨床應用主要透過國家腫瘤學會、區域報銷機制和不斷擴大的生物標記檢測來實現，但行政差異可能會影響用藥。在加拿大，循證應用透過國家和省級審查流程得到支持，公共報銷決策和伴隨診斷的可用性會影響患者何時獲得治療。俄羅斯PD-1和PD-L1抑制劑的用藥環境受到當地核准、採購政策、臨床指引和區域醫療保健資金籌措差異的影響。巴西是拉丁美洲最大的癌症醫療市場，免疫療法在私人醫療機構的普及率較高，並透過公共部門的評估和司法途徑的推進而逐步擴大。在墨西哥，癌症醫療需求不斷成長，查核點抑制劑在專科醫療機構的使用也在增加，但公立和私立醫療機構在服務取得方面存在差異。

為行業領導者提供的實用建議

行業領導者應優先考慮整合生物標記的策略，將臨床開發、診斷獲取和真實世界檢驗的創建相結合。關鍵措施包括投資於已驗證且可擴展的擴充性和補充診斷，以支持在PD-L1檢測、MSI-H/dMMR評估、腫瘤突變負荷和新型免疫特徵等方面進行合理的患者選擇。開發項目應強調基於腫瘤生物學特徵、抗藥性機制和可控毒性譜的合理聯合治療，而非基於寬泛​​經驗法則的聯合療法。相關人員應加強對免疫相關不利事件的真實世界安全性監測，包括標準化報告、臨床醫生教育、病患導航和多學科毒性管理。為提高公平獲取，各機構應設計能夠滿足衛生技術評估、療效比較、生活品質、治療順序和預算影響等方面要求的證據包，而不僅依賴臨床試驗的療效。區域策略必須反映當地的保險報銷系統、病理檢測能力、低溫運輸要求、腫瘤領域的人才儲備以及患者的支付能力。人工智慧和數位化工具的實施應確保臨床有效性、透明度和數據管治，以支援臨床試驗檢驗、影像審查、病理工作流程和上市後證據收集。領導者還需要透過整合臨床證據、服務模式、教育、藥物安全監測和治療路徑來強化差異化優勢，並做好應對生物相似藥物競爭和採購壓力的準備。

調查方法

本執行摘要採用二手調查方法撰寫，重點在於與PD-1和PD-L1抑制劑相關的檢驗且有資料支持的資訊來源。該研究途徑整合了公開的監管文件、臨床實踐指南、同行評審的癌症文獻、癌症機構資源、藥物安全監測資訊、衛生技術評估資料、臨床試驗註冊資訊以及國家和地區癌症政策參考資料。證據評估標準包括資訊來源的可靠性、發表的及時性、調查方法的品質、臨床相關性以及獨立參考文獻之間的一致性。本分析著重於已批准的治療用途、生物標記要求、治療路徑的演變、區域准入條件、政策趨勢以及免疫腫瘤學領域的技術驅動變革。為保持對定性和循證行業資訊的關注，本摘要特意排除了市場估算和預測。區域、群體和國家層面的洞察分析從醫療基礎設施、監管路徑、報銷機制、診斷系統、臨床試驗參與和癌症治療服務體係等方面進行解讀。該調查方法為策略決策提供了平衡的管理觀點，同時避免了未經證實的說法和推測性的數值預測。

結論

PD-1 和 PD-L1 抑制劑透過在日益廣泛的腫瘤類型和治療環境中實現持續的免疫介導反應，不斷重新定義癌症治療。該領域正朝著更早期的干預、篩選富含生物標記的患者、合理的聯合治療以及更精細的免疫相關毒性管理方向發展。區域部署不僅受法規核准的影響，還受保險報銷決策、診斷基礎設施、癌症醫療專業人員的可用性以及醫療保健系統狀況的影響。人工智慧、真實世界數據和先進的分子譜分析有望透過提高臨床試驗效率、患者匹配和治療監測，增強精準免疫腫瘤學，前提是必須維持嚴格的檢驗和管治標準。對於行業相關人員，最具吸引力的策略是將科學差異化與以可及性為導向的執行、整合診斷、負責任的數位化創新以及可靠的上市後證據相結合。隨著該治療領域的成熟，成功的關鍵在於提供具有臨床意義的療效、支持永續的醫療保健利用，以及在全球範圍內為合格的癌症患者提供公平的查核點抑製劑治療機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 PD-1 和 PD-L1 抑制劑市場：依產品類型分類

  • PD-1抑制劑
    • 半原發
    • Nivolumab
    • Pembrolizumab
  • PD-L1抑制劑
    • Atezolizumab
    • Avelumab
    • Durvalumab

第8章 PD-1 和 PD-L1 抑制劑市場：依適應症分類

  • 膀胱癌
  • 頭頸癌
  • 肺癌
  • 黑色素瘤
  • 腎臟細胞癌

第9章 PD-1 和 PD-L1 抑制劑市場：依給藥途徑分類

  • 靜脈
  • 皮下

第10章 PD-1 和 PD-L1 抑制劑市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第11章 PD-1 和 PD-L1 抑制劑市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 PD-1 和 PD-L1 抑制劑市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章 PD-1 和 PD-L1 抑制劑市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 PD-1 和 PD-L1 抑制劑市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Akeso Inc
  • Amgen Inc
  • AstraZeneca plc
  • BeiGene, Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Coherus Oncology, Inc.
  • CStone Pharmaceuticals
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Innovent Biologics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Sanofi SA
  • Shanghai Henlius Biotech, Inc.
  • Shanghai Junshi Biosciences Co Ltd
  • Sino Biopharmaceuticals
Product Code: MRR-4659C8713636

The PD-1 & PD-L1 Inhibitors Market is projected to grow by USD 114.95 billion at a CAGR of 14.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 43.30 billion
Estimated Year [2026] USD 49.61 billion
Forecast Year [2032] USD 114.95 billion
CAGR (%) 14.96%

PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors designed to restore anti-tumor T-cell activity by blocking the programmed cell death protein 1 pathway or its ligand-mediated immune evasion signals. These therapies have become a central pillar of immuno-oncology across multiple solid tumors and hematologic malignancies, supported by regulatory approvals, guideline integration, and extensive clinical evaluation in melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck cancer, hepatocellular carcinoma, gastric cancer, cervical cancer, triple-negative breast cancer, and microsatellite instability-high or mismatch repair-deficient tumors. The therapeutic class is increasingly shaped by biomarker-led treatment selection, including PD-L1 expression, tumor mutational burden, MSI-H/dMMR status, and emerging immune microenvironment signatures. Clinical practice is also moving from late-line metastatic use toward earlier-stage, neoadjuvant, adjuvant, and perioperative settings, where durable immune memory and improved event-free outcomes are major research priorities. For healthcare systems, payers, regulators, and biopharmaceutical stakeholders, the PD-1 and PD-L1 inhibitor landscape is defined by scientific innovation, expanding combination strategies, safety management requirements, and the need to improve equitable patient access while preserving evidence-based use.

Transformative Shifts in the PD-1 and PD-L1 Inhibitor Landscape

The PD-1 and PD-L1 inhibitor landscape is undergoing major transformation as clinical development shifts from monotherapy toward rational combinations with chemotherapy, anti-angiogenic agents, targeted therapies, radiation, cancer vaccines, cellular therapies, and next-generation immunomodulators. Earlier intervention is a defining change, with checkpoint blockade being evaluated and used in neoadjuvant, adjuvant, and perioperative protocols where pathologic response, event-free survival, and long-term recurrence reduction are key endpoints. Precision oncology is also reshaping treatment pathways as biomarker testing becomes more standardized and multidimensional, moving beyond single-marker PD-L1 immunohistochemistry toward composite immune profiling, genomic instability markers, circulating tumor DNA, and resistance signatures. At the same time, the sector is responding to immune-related adverse events through improved monitoring, multidisciplinary care models, and steroid-sparing management approaches. Regulatory science is adapting to tumor-agnostic indications, confirmatory evidence requirements, real-world evidence generation, and accelerated access mechanisms. Another important shift is the emergence of biosimilar and domestically developed checkpoint inhibitors in several jurisdictions, which is intensifying policy focus on affordability, interchangeability, procurement standards, pharmacovigilance, and treatment continuity.

Cumulative Impact of Artificial Intelligence on Checkpoint Inhibitor Development

Artificial intelligence is becoming increasingly relevant across the PD-1 and PD-L1 inhibitor value chain, particularly in biomarker discovery, patient stratification, clinical trial optimization, medical imaging analytics, and real-world evidence interpretation. Machine learning models are being applied to digital pathology, radiomics, genomics, transcriptomics, and electronic health records to identify immune-responsive tumor phenotypes and refine prediction of treatment benefit or resistance. In clinical development, AI can support protocol design, eligibility refinement, site feasibility analysis, patient matching, adverse event signal detection, and adaptive trial monitoring. In clinical practice, AI-enabled decision support has potential to help clinicians integrate PD-L1 status, molecular test results, prior treatments, comorbidities, organ function, and immune toxicity risk into evidence-aligned care pathways. However, responsible implementation requires transparent model validation, diverse training datasets, regulatory oversight, explainability, cybersecurity, and safeguards against algorithmic bias. The cumulative impact of AI is not a replacement for clinical judgment but an acceleration of precision immuno-oncology, helping convert complex biological and real-world data into more timely, reproducible, and patient-centered treatment decisions.

Key Regional Insights Across Global PD-1 and PD-L1 Inhibitor Adoption

Asia-Pacific is a highly active region for PD-1 and PD-L1 inhibitors due to large oncology patient populations, rapid clinical trial expansion, increasing biomarker testing capacity, and strong regulatory engagement in immuno-oncology. China has accelerated domestic checkpoint inhibitor development and approvals, while Japan, South Korea, Australia, India, and Southeast Asian markets continue to expand guideline-based adoption at different speeds according to reimbursement, diagnostic infrastructure, and oncology workforce capacity. Europe demonstrates strong evidence-based adoption through centralized regulatory evaluation, health technology assessment, national reimbursement negotiations, and expanding biomarker testing networks, while country-level access can vary due to cost-effectiveness thresholds and healthcare budget priorities. North America remains one of the most mature regions for PD-1 and PD-L1 inhibitor use, supported by advanced cancer centers, comprehensive molecular diagnostics, payer scrutiny, extensive clinical trial infrastructure, and broad incorporation of immunotherapy into oncology guidelines. Latin America is characterized by growing clinical expertise and rising demand for immuno-oncology, although access differs substantially across public and private systems, with reimbursement timelines, pathology standardization, and drug procurement policies shaping availability. Africa is an emerging immuno-oncology access region where progress depends on oncology infrastructure, pathology capacity, financing mechanisms, cold-chain logistics, cancer registry development, and regional partnerships to improve diagnosis and treatment delivery. The Middle East is investing in oncology modernization, specialized cancer centers, and precision medicine programs, particularly in high-income Gulf health systems, while broader regional access remains linked to reimbursement design and specialist availability.

Key Group Insights Shaping Immuno-Oncology Access and Policy

NATO member states collectively include many advanced oncology systems with mature clinical trial networks and guideline adoption, but immunotherapy access is still shaped by national healthcare financing, public health priorities, and country-specific regulatory or reimbursement pathways. The G7 countries generally have strong regulatory, diagnostic, clinical research, and reimbursement ecosystems that support evidence-based use of PD-1 and PD-L1 inhibitors, although payer evaluation and value-based access policies remain influential. BRICS countries show diverse trajectories: China has built extensive domestic development capabilities, India is expanding oncology access while balancing affordability, Brazil is integrating immunotherapy within segmented public and private pathways, Russia maintains local regulatory and procurement dynamics, and South Africa faces infrastructure and financing constraints alongside growing clinical expertise. The European Union provides a structured environment for checkpoint inhibitor evaluation through centralized authorization, pharmacovigilance, and health technology assessment processes, while individual member states determine reimbursement conditions and real-world access. Within ASEAN, PD-1 and PD-L1 inhibitor adoption is advancing through national cancer control efforts, private-sector oncology services, and participation in multinational trials, but access remains uneven because biomarker testing, reimbursement coverage, and specialist distribution differ across member states. The GCC is strengthening immuno-oncology access through investment in tertiary cancer care, national insurance frameworks, and precision medicine initiatives, with high-income systems often prioritizing rapid adoption of guideline-recommended therapies.

Key Country Insights for PD-1 and PD-L1 Inhibitor Implementation

China has become a major immuno-oncology hub with extensive domestic development, broad clinical trial activity, and evolving reimbursement inclusion, while the United States remains a leading clinical and regulatory environment for PD-1 and PD-L1 inhibitors, with broad use across approved tumor types, advanced biomarker testing, high clinical trial activity, and strong real-world evidence generation, though access is influenced by insurance design and utilization management. Japan maintains high standards for clinical evidence, pharmacovigilance, and reimbursement, with strong uptake in approved indications and active research in gastric, lung, and other cancers common in the region. India is expanding checkpoint inhibitor use in tertiary oncology centers, with affordability, out-of-pocket spending, biosimilar availability, and molecular diagnostic access playing decisive roles. Germany benefits from strong oncology infrastructure, early access mechanisms after authorization, and structured benefit assessment, while the United Kingdom integrates PD-1 and PD-L1 inhibitors through rigorous health technology assessment, managed access arrangements, national guidelines, and molecular testing programs. Australia supports guideline-led access through public reimbursement and strong oncology networks, and France combines centralized evaluation with national reimbursement pathways and robust cancer networks. South Korea combines advanced cancer care, biomarker testing, and active clinical research with national reimbursement evaluation. Italy and Spain demonstrate established clinical adoption through national oncology societies, regional reimbursement mechanisms, and expanding biomarker testing, though administrative variability can affect access. Canada supports evidence-based adoption through national and provincial review processes, with public reimbursement decisions and companion diagnostic availability affecting patient access timelines. Russia's PD-1 and PD-L1 inhibitor environment is shaped by local registration, procurement policies, clinical guidelines, and regional healthcare funding differences. Brazil represents the largest oncology environment in Latin America, where immunotherapy availability is stronger in private healthcare and expanding gradually through public-sector evaluation and judicial access dynamics. Mexico has growing oncology demand and increasing checkpoint inhibitor use in specialized settings, although access differs across public institutions and private care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-integrated strategies that align clinical development, diagnostic access, and real-world evidence generation. A key action is to invest in validated, scalable companion and complementary diagnostics that support appropriate patient selection across PD-L1 testing, MSI-H/dMMR assessment, tumor mutational burden, and emerging immune signatures. Development programs should emphasize rational combinations based on tumor biology, resistance mechanisms, and manageable toxicity profiles rather than broad empirical pairing. Stakeholders should strengthen real-world safety monitoring for immune-related adverse events, including standardized reporting, clinician education, patient navigation, and multidisciplinary toxicity management. To improve equitable access, organizations should design evidence packages that address health technology assessment requirements, comparative effectiveness, quality of life, treatment sequencing, and budget impact without relying solely on trial efficacy. Regional strategies should reflect local reimbursement systems, pathology capacity, cold-chain requirements, oncology workforce availability, and patient affordability. AI and digital tools should be deployed with clinical validation, transparency, and data governance to support trial recruitment, imaging review, pathology workflows, and post-market evidence. Leaders should also prepare for biosimilar competition and procurement pressure by strengthening differentiation through clinical evidence, service models, education, pharmacovigilance, and treatment pathway integration.

Research Methodology

This executive summary is developed using a secondary research methodology focused on verified, data-backed sources relevant to PD-1 and PD-L1 inhibitors. The research approach synthesizes publicly available regulatory documents, clinical practice guidelines, peer-reviewed oncology literature, cancer agency resources, pharmacovigilance communications, health technology assessment materials, clinical trial registry information, and national or regional oncology policy references. Evidence is assessed for source credibility, publication recency, methodological quality, clinical relevance, and consistency across independent references. The analysis emphasizes approved therapeutic use, biomarker requirements, treatment pathway evolution, regional access conditions, policy dynamics, and technology-enabled transformation in immuno-oncology. Market estimation, market sizing, market share, and forecasting are intentionally excluded to maintain focus on qualitative, evidence-based industry intelligence. Regional, group, and country insights are interpreted through the lens of healthcare infrastructure, regulatory pathways, reimbursement systems, diagnostic readiness, clinical trial participation, and oncology care delivery. This methodology supports a balanced executive view for strategic decision-making while avoiding unsupported claims or speculative numerical projections.

Conclusion

PD-1 and PD-L1 inhibitors continue to redefine cancer treatment by enabling durable immune-mediated responses across a widening range of tumor types and treatment settings. The field is moving toward earlier-stage intervention, biomarker-rich patient selection, rational combination therapy, and more sophisticated management of immune-related toxicity. Regional adoption is shaped not only by regulatory approvals but also by reimbursement decisions, diagnostic infrastructure, oncology workforce capacity, and health system readiness. Artificial intelligence, real-world evidence, and advanced molecular profiling are expected to strengthen precision immuno-oncology by improving trial efficiency, patient matching, and treatment monitoring, provided that validation and governance standards are rigorously maintained. For industry stakeholders, the most defensible strategy is to combine scientific differentiation with access-oriented execution, diagnostic integration, responsible digital innovation, and robust post-market evidence. As the therapeutic class matures, success will depend on delivering clinically meaningful outcomes, supporting sustainable healthcare use, and expanding equitable access to checkpoint inhibitor therapy for eligible cancer patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. PD-1 & PD-L1 Inhibitors Market, by Product Type

  • 7.1. Introduction
  • 7.2. PD-1 Inhibitor
    • 7.2.1. Cemiplimab
    • 7.2.2. Nivolumab
    • 7.2.3. Pembrolizumab
  • 7.3. PD-L1 Inhibitor
    • 7.3.1. Atezolizumab
    • 7.3.2. Avelumab
    • 7.3.3. Durvalumab

8. PD-1 & PD-L1 Inhibitors Market, by Indication

  • 8.1. Introduction
  • 8.2. Bladder Cancer
  • 8.3. Head And Neck Cancer
  • 8.4. Lung Cancer
  • 8.5. Melanoma
  • 8.6. Renal Cell Carcinoma

9. PD-1 & PD-L1 Inhibitors Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. PD-1 & PD-L1 Inhibitors Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Research Institutes
  • 10.4. Specialty Clinics

11. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. PD-1 & PD-L1 Inhibitors Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. PD-1 & PD-L1 Inhibitors Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. PD-1 & PD-L1 Inhibitors Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Akeso Inc
  • 16.2. Amgen Inc
  • 16.3. AstraZeneca plc
  • 16.4. BeiGene, Ltd.
  • 16.5. Boehringer Ingelheim International GmbH
  • 16.6. Bristol-Myers Squibb Company
  • 16.7. Coherus Oncology, Inc.
  • 16.8. CStone Pharmaceuticals
  • 16.9. Eisai Co., Ltd
  • 16.10. Eli Lilly and Company
  • 16.11. F. Hoffmann-La Roche AG
  • 16.12. Gilead Sciences Inc
  • 16.13. GlaxoSmithKline plc
  • 16.14. Incyte Corporation
  • 16.15. Innovent Biologics Inc
  • 16.16. Jiangsu Hengrui Medicine Co Ltd
  • 16.17. Merck & Co Inc
  • 16.18. Novartis AG
  • 16.19. Ono Pharmaceutical Co., Ltd.
  • 16.20. Pfizer Inc
  • 16.21. Regeneron Pharmaceuticals Inc
  • 16.22. Sanofi S.A.
  • 16.23. Shanghai Henlius Biotech, Inc.
  • 16.24. Shanghai Junshi Biosciences Co Ltd
  • 16.25. Sino Biopharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PD-1 INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PD-1 INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PD-1 INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CEMIPLIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CEMIPLIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CEMIPLIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NIVOLUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NIVOLUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NIVOLUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PD-L1 INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PD-L1 INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PD-L1 INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AVELUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AVELUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AVELUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DURVALUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DURVALUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DURVALUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLADDER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLADDER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLADDER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEAD AND NECK CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEAD AND NECK CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEAD AND NECK CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 132. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 133. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 189. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 190. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 197. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 198. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 221. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 222. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 237. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 238. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 291. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025